SCHEMBL9040852

SCHEMBL9040852

Cc1ccc(N)c2c1CCCC2=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 13/20 0.48
DRD4 P21917 1/20 0.40
CREBBP Q92793 2/20 0.39
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
BRDT Q58F21 1/20 0.38
CECR2 Q9BXF3 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
BRD7 Q9NPI1 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274983 0.88 BRD4 (0.47) BRD4DRD4CREBBPMAPTLMNA
SCHEMBL29396153 0.88 BRD4 (0.47) BRD4DRD4CREBBPMAPTLMNA
SCHEMBL7098070 0.86 BRD4 (0.49) BRD4CREBBPMAPTLMNABRDT
SCHEMBL22463115 0.86 BRD4 (0.44) BRD4CREBBPMAPTLMNATHRB
Hydrochloric Acid SCHEMBL9868389 0.84 BRD4 (0.43) BRD4CREBBPMAPTLMNATHRB
Hydrochloric Acid SCHEMBL9404876 0.79 CSNK2A2 (0.47) BRD4CREBBPMAPTLMNATHRB
SCHEMBL9040886 0.79 BRD4 (0.43) BRD4CREBBPMAPTLMNATHRB
SCHEMBL22519655 0.79 BRD4 (0.40) BRD4CREBBPMAPTLMNATHRB
SCHEMBL9041741 0.79 ALDH1A1 (0.59) BRD4MAPTLMNATHRBALDH1A1
Hydrochloric Acid SCHEMBL9404913 0.78 ALDH1A1 (0.57) BRD4MAPTLMNATHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239894-A1 THERAPEUTIC BINDING MOLECULES MEDIMMUNE LIMITED (GB) 2024-07-18 US disclosed
US-11795225-B2 Therapeutic binding molecules MEDIMMUNE LIMITED (GB) 2023-10-24 US disclosed
EP-0471358-B1 Fluoroethylcamptothecin derivatives KYORIN SEIYAKU KK (JP) 1996-05-08 EP disclosed
EP-0471358-A1 Fluoroethylcamptothecin derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 1992-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795225-B2 Therapeutic binding molecules EPCAM, IGSF11, FCGR3B BRD4 691/4885DRD4 1614/4885CREBBP 1879/4885
US-20240239894-A1 THERAPEUTIC BINDING MOLECULES EPCAM, IGSF11, FCGR3B BRD4 691/4885DRD4 1614/4885CREBBP 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.